ZEPZELCA may be used when your lung cancer: has spread to other parts of the body (metastatic),and you have received treatment with chemotherapy that contains platinum, and it did not work or is no longer working. ZEPZELCA is approved based on response rate and how long the response last...
Small cell lung cancerchemotherapyrecurrent small cell lung cancerchest radiotherapyprophylactic cranial irradiationSmall cell lung cancer (SCLC) is a lethal disease for which there have been only small advances in diagnosis and treatment in t...
Can benign lung nodules become cancerous? DISCLAIMER: The information provided on this website is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. The use of this website does not create a doctor-patient relationsh...
lung cancer; small cell lung cancer; treatment Abstract: Lung cancer was relatively uncommon at the turn of the 20th century, and has increased in prevalence at alarming rates, particularly because of the augmented trend in smoking, so that it is now the most common cause of cancer death in...
The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.
For more than three decades, care for small-celllung cancer(SCLC) remained mostly the same. That’s changing now -- doctors have a new option called immunotherapy. This line of treatment uses your body’s own immune system to fight cancer. ...
Small cell lung cancer (SCLC) is a lethal disease for which there have been only small advances in diagnosis and treatment in the past decade. Our goal was to revise the evidence-based guidelines on staging and best available treatment options. A comprehensive literature search covering 2004 to...
Conference|WCLC - World Conference on Lung Cancer An overview of the potential treatment strategies for patients were presented at the 2024 World Conference on Lung Cancer. At the World Conference on Lung Cancer 2024 in San Diego, California, Daichi Fujimoto, MD, PhD, ...
[5] DINGEMANS A C, FR H M, ARDIZZONI A, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(☆) [J]. Annals of oncology : official journal of the European Society for Medical Oncology, 2021, 32(7): 839-53. ...
EORTC(European Organization for Research and Treatment of Cancer)的一项研究,将对化疗有反应的患者随机化分为2组,接受PCI或不接受PCI,发现PCI治疗组1年生存率为27.1%,未接受PCI者为13.3%。[49]在该研究中,PCI不仅减少脑转移的发生率也提高无病生存率和总体生存率。然而,欧洲肿瘤医学学会(ESMO)2010年的实践...